Direct costs of ankylosing spondylitis and its determinants: an analysis among three European countries.

Date publication

août 2003

Journal

Annals of the rheumatic diseases

Auteurs

Membres identifiés du Cancéropôle Est :
Pr GUILLEMIN Francis

Tous les auteurs :
Boonen A, van der Heijde D, Landewé R, Guillemin F, Rutten-van Mölken M, Dougados M, Mielants H, de Vlam K, van der Tempel H, Boesen S, Spoorenberg A, Schouten H, van der Linden S

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/12860728

Résumé

To assess direct costs associated with ankylosing spondylitis (AS). To determine which variables, including country, predict costs.

Mots clés

Adolescent, Adult, Aged, Antirheumatic Agents, economics, Belgium, Cost of Illness, Direct Service Costs, statistics & numerical data, Drug Costs, Female, Follow-Up Studies, France, Health Expenditures, statistics & numerical data, Health Services, utilization, Humans, Male, Middle Aged, Netherlands, Prospective Studies, Severity of Illness Index, Spondylitis, Ankylosing, economics, Statistics as Topic, Surveys and Questionnaires

Référence

Ann. Rheum. Dis.. 2003 Aug;62(8):732-40